CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Zinc SulfateWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (4)

Name (Synonyms) Correlation
drug272 ECCO2R Wiki 1.00
drug269 Doxycycline Wiki 0.71
drug82 Azithromycin Wiki 0.21
drug360 Hydroxychloroquine Wiki 0.13

Correlated MeSH Terms (3)

Name (Synonyms) Correlation
D055371 Acute Lung Injury NIH 0.16
D012127 Respiratory Distress Syndrome, Newborn NIH 0.15
D012128 Respiratory Distress Syndrome, Adult NIH 0.13

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 A Randomized Study Evaluating the Safety and Efficacy of Hydroxychloroquine and Zinc in Combination With Either Azithromycin or Doxycycline for the Treatment of COVID-19 in the Outpatient Setting

This is a randomized, open-label trial to assess the safety and efficacy of hydroxychloroquine, and zinc in combination with either azithromycin or doxycycline in a higher risk COVID-19 positive outpatient population.

NCT04370782 COVID-19 Drug: Hydroxychloroquine Drug: Azithromycin Drug: Zinc Sulfate Drug: Doxycycline

Primary Outcomes

Description: Patients will be assessed on day 5 for when COVID-19 symptoms completely resolve compared to baseline (day 1 of trial)

Measure: Time to Resolution of Symptoms relative to baseline (day 1 of trial)

Time: Day 5

Description: Patients will be assessed on day 14 for when COVID-19 symptoms completely resolve compared to baseline (day 1 of trial)

Measure: Time to Resolution of Symptoms relative to baseline (day 1 of trial)

Time: Day 14

Description: Patients will be assessed on day 21 for when COVID-19 symptoms completely resolve compared to baseline (day 1 of trial)

Measure: Time to Resolution of Symptoms relative to baseline (day 1 of trial)

Time: Day 21

Description: Number of participants hospitalized and/or requiring repeat ER visits related to COVID-19 complications

Measure: Number of participants hospitalized and/or requiring repeat ER visits

Time: 21 days

Description: If hospitalized, number of participants admitted to the ICU, and number of days in the ICU

Measure: ICU Length of Stay

Time: Until Discharged up to 30 days

Description: If placed on ventilator, number of days on a ventilator

Measure: Ventilator

Time: Until extubated up to 30 days

Secondary Outcomes

Description: Severity of symptoms evaluated at day 5, day 14, and day 21 scored by the participant for feverishness, sore throat, cough, shortness of breath, myalgias. (0 =none; 1 = mild; 2 = moderate; 3 = severe)

Measure: Severity of symptoms

Time: Day 5, Day 14, and Day 21

Description: Number of participants with adverse events due to drug regimen

Measure: Number of participants with adverse events due to drug regimen

Time: 21 days

Description: Assess all patients to evaluate for QTc prolongation >500ms

Measure: Number of participants with QTc prolongation >500ms

Time: Days 1 thru 5, Day 10, Day 21

No related HPO nodes (Using clinical trials)